Case Study

Disease Area Strategy: Business Development (BD) Assessment

Prescient developed a BD assessment framework to identify attractive candidates in an oncology indication with a high unmet need.

Client Situation

The client, a large biotech company, was seeking opportunities to strengthen its portfolio and drive the development of therapies for an oncology indication with a high unmet need.

The client sought to develop a tailored BD framework to assess assets in development that might be attractive “targets” to enhance its portfolio. Given that the therapeutic area of interest was quickly evolving and that other key players were likely interested in these assets, rapid development and alignment on this framework was essential.
Prescient’s Approach

Leveraging Prescient’s insights into market and competitive intelligence, we conducted an exhaustive review of the oncology treatment landscape and pipeline to identify the “universe” of potential assets for consideration.

Working in close collaboration with the client’s functional team (business development, R&D, etc.), we developed a BD framework to evaluate assets against key criteria, including the strength of the clinical profile and BD feasibility.

This framework was utilized to yield a short list of assets for consideration to help the client advance through the due diligence process.
Results and Solutions

The Prescient team moderated a cross-functional workshop to pressure-test the BD framework with an existing pool of assets to assess the potential and prioritize five oncology assets of interest.

By the end of this engagement, the client team aligned on the BD framework and a short list of assets for potential partnership consideration.

CLIENT IMPACT

This BD framework has since been applied across multiple disease areas to guide future BD decisions.

Case Study

Indication Sequencing: Assessing a Product’s Potential across Multiple Indications to Identify the Optimal Indication Sequencing

Our client was developing a novel cellular therapy with promising Phase I safety data and

Case Study

Asset Attractiveness Assessment: Licensing Due Diligence of an Asset in Development for a Rare Disease

Our client, a global specialty pharmaceutical company, was seeking to evaluate the clinical and commercial

Case Study

Medical Strategy and Planning: Medical Planning

Prescient helped accelerate, assure and simplify the client’s annual medical affairs strategic planning across its solid tumor franchise.

Case Study

Disease Area Strategy: Business Development (BD) Assessment

CLIENT IMPACT

This BD framework has since been applied across multiple disease areas to guide future BD decisions.

Related content

Indication Sequencing: Assessing a Product’s Potential across Multiple Indications to Identify the Optimal Indication Sequencing

Asset Attractiveness Assessment: Licensing Due Diligence of an Asset in Development for a Rare Disease

Medical Strategy and Planning: Medical Planning